|Day Low/High||0.01 / 0.01|
|52 Wk Low/High||0.01 / 0.04|
Your questions are answered in our latest addition of the biotech mailbag.
I'll answer some of frequent questions I am hearing from readers in recent weeks.
I continue to believe that biotech and biopharma stocks will outperform in 2018.
3pm blog update Heading into the homestretch of the trading week. All the major indices remain firmly in the green. Small biotech is having a very strong day, up about two percent this Friday. Some small cap movers today. Synergy Pharmaceuticals nic...
We are coming my favorite part of earnings season -- when these small-caps report.
Not much in the way of trading action to begin the new week. All indices are down slightly an hour into trading this Monday. Individual names are moving on company-specific news and analyst commentary. Oil continues to show strength to start the wee...
Winning FDA approval isn't always a win.
The experiences of three biotechs show how drug approvals don't always translate into stock gains.
T2 Biosystems and Synergy Pharmaceuticals offer promising prospects at reasonable prices.
We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.
The sector decisively has pushed through upward resistance levels in place for many months.
The major indices continue to trade near even as we close out the week in a rather dull day of trading given June options expiration. The Russell 2000 is down more than a half percent today as large-caps continue to outperform small-caps by a wide m...
Tech meltdown provides an opportunity for rotation into undervalued sectors.
Synergy Pharmaceuticals, Trevena and Egalet seem to have worst-case scenarios priced into them.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
Both pharma companies are promising names that easily could become buyout targets.
The market continues to be in rally mode as everyone watches the presidential inauguration ceremonies. Biotech is not participating in the rally. Bristol Myers-Squibb is one reason the sector is not participating, as its key oncology drug Opdivo wil...